On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

Investigating Tyrosine Kinase Inhibitors for ITP

In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators shared updates on two kinase inhibitors for the treatment...
On location

ADAMTS13 Activity Levels Predict iTTP Recurrence

A study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress confirms the value of longitudinal quarterly assessment of ADAMTS13...
On location

Studies Confirm Long-Term Benefit of Gene Therapy for Hemophilia A

In two studies presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress, gene therapies for hemophilia A demonstrated durable increases...
On location

Is It Time for a Paradigm Shift for CAPS Treatment?

Newer treatment approaches that incorporate monoclonal antibodies reduce the mortality risk in patients with catastrophic antiphospholipid syndrome (CAPS), according to research presented at the...
On location

Late-Breaking Abstracts Address Thrombosis and COVID-19

A growing body of clinical evidence indicates that COVID-19 infection predisposes patients to arterial and venous thrombosis and thrombotic complications. At the International Society...
On location

Extended Half-Life Factor VIII Fusion Protein Effective in Previously Untreated Hemophilia A

The use of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) appeared to be safe and effective in young boys with previously untreated...
On location

FLT180a: A New Gene Therapy Candidate for Severe Hemophilia B

In a small study of patients with severe hemophilia B, the novel adeno-associated virus (AAV) gene therapy FLT180a was associated with increased factor IX...
On location

Decitabine Plus Venetoclax Outperforms Intensive Chemotherapy Across Risk Groups

For older and unfit patients with acute myeloid leukemia (AML), venetoclax plus hypomethylating agents (HMAs) have been established as a standard of care and...
On location

Phase I Trial Supports CC-92480 for Heavily Pretreated Myeloma

Results from a first-in-human trial of CC-92480 in patients with relapsed or refractory multiple myeloma show a manageable safety profile and promising efficacy, according...
On location

Caplacizumab Produces Faster, Sustained Platelet Count Responses Than Placebo in aTTP

Patients with acquired thrombotic thrombocytopenic purpura (aTTP) who were treated with caplacizumab – anti–von Willebrand factor humanized immunoglobulin – experienced a faster and more...
Advertisement

Current Issue

October 2020 Volume 6, Issue 12

This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.

Block title